Immunomedics Inc. (NASDAQ: IMMU) was raised to Buy from Hold and the price target was raised handily to $5.00 from $1.50 at Jefferies. Wells Fargo maintained its Outperform rating with a valuation range of $3.00 to $3.50, noting that IMMU132 has emerged as a major value driver accelerating its approval potential. The stock closed down 7.5% at $3.46 on Thursday. Its 52-week range is $1.50 to $5.05.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.